Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.
Timothy J TurnerPricilla BrunRoss C GruberDimitry OfengeimPublished in: Drugs in R&D (2024)
Tolebrutinib was the only candidate of the three that attained relevant CSF exposure in non-human primates.